Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)

Docbot

Attachments

*Architects: Cancer & Oncology Companies_Diagnostics, Treatment, Health IT
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
*Industry: Southern California
Venture Capital: Series A

2021: Gastrointestinal AI developer Docbot nets new CEO, series A funding for clinical trials
2022: $4 million in Series A funding from a round led by Khosla Ventures, plus additional backing from Bold Capital Partners, Collaborative Fund and Boutique Venture Partners
Irvine, California
The company is developing its machine vision algorithms to pick out signs of conditions spanning multiple organs from video recordings—such as detection and classification of potentially cancerous polyps in the colon, as well as evidence of Barrett’s esophagus, esophageal cancer or stomach cancer
UltivisionAI program for spotting diseases across the entire GI tract.